Therapy News and Research

RSS

Experimental drug Rova-T shows safety, efficacy in treating advanced SCLC patients

The experimental "smart-bomb" drug rovalpituzumab tesirine (Rova-T) appears safe and shows efficacy in treating patients with advanced small cell lung cancer (SCLC), according to results from a first-in-human clinical trial to be presented today by a Memorial Sloan Kettering Cancer Center researcher at the 2016 American Society of Clinical Oncology Annual Meeting in Chicago.

6 Jun 2016

New research reveals advances that could change gynecologic cancer standard-of-care treatments

Advances that could change gynecologic cancer standard-of-care treatments are the centerpiece of key studies being presented by researchers from The University of Texas MD Anderson Cancer Center's Department of Gynecologic Oncology and Reproductive Medicine at the 2016 Annual Meeting of the American Society of Clinical Oncology.

6 Jun 2016

Nivolumab drug shows better response rate in metastatic bladder cancer patients

The immune checkpoint blockade drug nivolumab reduced tumor burden in 24.4 percent of patients with metastatic bladder cancer, regardless of whether their tumors had a biomarker related to the drug's target, according to clinical trial results from The University of Texas MD Anderson Cancer Center.

6 Jun 2016

Mastectomy followed by standard therapy improves survival in stage IV breast cancer patients

Surgery to remove the primary tumor in women diagnosed with stage IV breast cancer, followed by the standard combination of therapies, adds months to the patients' lives, compared with standard therapy alone, an international clinical trial led by a University of Pittsburgh Cancer Institute professor revealed.

4 Jun 2016

Researchers prove existence of olfactory receptor in pigment-producing skin cells

Researchers at Ruhr-Universität Bochum were the first ones to prove the existence of an olfactory receptor in pigment-producing cells in human skin, the so-called melanocytes. The team headed by Prof Dr Dr Dr habil. Hanns Hatt demonstrated that the violet-like scent Beta-Ionone can activate the receptor.

4 Jun 2016

Neutral atherosclerosis trial highlights effectiveness of optimal medical therapy

Salsalate has no greater effect than placebo on the progression of coronary artery plaque, show the findings of the randomised TINSAL-CVD trial.

3 Jun 2016

UZH scientists identify new class of protein compounds to treat HER2-positive breast cancer

In Switzerland alone, more than 5,700 women are diagnosed with breast cancer each year, and almost 1,400 of those affected die of the disease. In many very invasive forms of breast cancer, the cells have too much of the receptor HER2 on their surface.

3 Jun 2016

Lower quantities of CD74 protein in placentas of preeclamptic women can impact fetal development

Preeclampsia is one of the most common complications to occur during pregnancy, yet its causes are still unknown. A new study involving patients, cell cultures and animal experiments has now shown that those affected by the disease have lower quantities of the placenta's immune protein CD74, and that certain inflammatory factors are higher. These factors disrupt the formation of the placenta and leave the fetus undernourished.

3 Jun 2016

Clinical study finds two topical skin creams as effective noninvasive treatments for low-risk superficial BCC

Basal cell carcinoma is one of the most common cancers and its incidence is increasing worldwide, putting a significant burden on health services. Topical treatments are available for superficial basal cell carcinoma (BCC) but there has a lack of long-term follow-up data to guide treatment decisions.

3 Jun 2016

Mayo study finds mechanism by which Pten safeguards against tumor formation

Pten (short for phosphatase and tensin homolog) is a tumor suppressor that is defective in about 20-25 percent of all patients with cancers. Mayo Clinic researchers now have discovered that Pten safeguards against tumor formation by keeping chromosome numbers intact when a cell splits into two daughter cells.

3 Jun 2016

Scientists use new technique to repair fibrotic liver cells within the organ

Advances in stem cell research have made it possible to convert patients' skin cells into heart cells, kidney cells, liver cells and more in the lab dish, giving researchers hope that one day such cells could replace organ transplantation for patients with organ failure.

3 Jun 2016

Stimulating STING pathway to provoke life-extending immune response shows promise in AML

A protein known as STING plays a crucial role in the immune system's ability to "sense" cancer by recognizing and responding to DNA from tumor cells. Injection of compounds that activate the STING pathway directly into solid tumors in mice has been shown in prior studies to result in very potent anti-tumor immune responses.

3 Jun 2016

Immunotherapy with experimental monoclonal antibody could reduce neuroblastoma tumors

Neuroblastoma tumors shrank, some dramatically, in 80 percent of newly diagnosed, young, high-risk patients enrolled in a Phase II clinical trial that included an experimental monoclonal antibody. The immunotherapy agent was produced on the St. Jude Children's Research Hospital campus where the study is still underway.

3 Jun 2016

Analysing blood metabolites may help monitor effects of novel drugs

Testing for metabolic changes in the blood could indicate whether a cancer drug is working as designed, a new study reports.

3 Jun 2016

CNIO researchers avoid genetic manipulation to create lab mice with extra-long telomeres

The Telomeres and Telomerase Group at the Spanish National Cancer Research Centre, in collaboration with the Centre's Transgenic Mice Core Unit, has succeeded in creating mice in the laboratory with hyper-long telomeres and with reduced molecular ageing, avoiding the use of what to date has been the standard method: genetic manipulation.

3 Jun 2016

Retroviral replicating vector can extend lives of brain cancer patients

Doctors at UCLA, Cleveland Clinic, University of California San Diego School of Medicine and additional institutions have achieved a milestone in the development of a treatment for people with recurrent glioblastoma, the most common and aggressive form of brain cancer, by successfully demonstrating a modified virus that can extend the lives of patients with the disease.

2 Jun 2016

Therapy News and Research

Experimental drug Rova-T shows safety, efficacy in treating advanced SCLC patients

New research reveals advances that could change gynecologic cancer standard-of-care treatments

Nivolumab drug shows better response rate in metastatic bladder cancer patients

Mastectomy followed by standard therapy improves survival in stage IV breast cancer patients

Researchers prove existence of olfactory receptor in pigment-producing skin cells

Neutral atherosclerosis trial highlights effectiveness of optimal medical therapy

UZH scientists identify new class of protein compounds to treat HER2-positive breast cancer

Lower quantities of CD74 protein in placentas of preeclamptic women can impact fetal development

Clinical study finds two topical skin creams as effective noninvasive treatments for low-risk superficial BCC

Mayo study finds mechanism by which Pten safeguards against tumor formation

Scientists use new technique to repair fibrotic liver cells within the organ

Stimulating STING pathway to provoke life-extending immune response shows promise in AML

Immunotherapy with experimental monoclonal antibody could reduce neuroblastoma tumors

Analysing blood metabolites may help monitor effects of novel drugs

CNIO researchers avoid genetic manipulation to create lab mice with extra-long telomeres

Retroviral replicating vector can extend lives of brain cancer patients

Some women with ovarian cancer do not receive beneficial surgical treatment, study finds

Woman with higher BMI can face more challenges to being physically active

Study uncovers racial, working class discrimination in private mental health care market

Advanced imaging kit Netspot gets FDA approval to detect rare neuroendocrine tumors

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News